Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coronary Bifurcation PCI-Part II: Advanced Considerations.

Journal of cardiovascular development and disease·2025
Same author

Coronary Bifurcation PCI-Part I: Fundamentals.

Journal of cardiovascular development and disease·2025
Same author

Intravenous iron therapy for patients with iron deficiency and heart failure: a systematic review and meta-analysis of randomized controlled trials.

Proceedings (Baylor University. Medical Center)·2024
Same author

Progressive dyspnoea in a patient with neuroendocrine tumor: do invasive haemodynamics help?

Heart (British Cardiac Society)·2023
Same author

Hypothermia as an Adjunctive Therapy to Percutaneous Intervention in ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Control Trials.

Cardiovascular revascularization medicine : including molecular interventions·2022
Same author

Heavy lone coronary artery thrombosis treated by stent retriever, in the setting of COVID-19 infection.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2022

Related Experiment Video

Updated: Jun 9, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Periprocedural myocardial infarction: review and classification.

Elias B Hanna1, Thomas A Hennebry

  • 1Department of Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. ehanna10@yahoo.com

Clinical Cardiology
|August 25, 2010
PubMed
Summary

Periprocedural myocardial infarction (PMI) after percutaneous coronary interventions (PCI) still occurs, impacting survival. While definitions vary, elevated cardiac biomarkers indicate worse prognosis and reflect unstable atherosclerosis.

More Related Videos

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice
08:28

Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice

Published on: January 19, 2022

Related Experiment Videos

Last Updated: Jun 9, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice
08:28

Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice

Published on: January 19, 2022

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiovascular Research

Background:

  • Technical and pharmacologic advancements have decreased large periprocedural myocardial infarction (PMI) rates post-percutaneous coronary intervention (PCI).
  • Despite improvements, PMI still occurs in 6-18% of PCI cases, significantly impacting short- and long-term patient survival.
  • PMI is often linked to atheroembolization into the microcirculation, even after seemingly uncomplicated PCI procedures.

Purpose of the Study:

  • To review the incidence, mechanisms, diagnostic criteria, and prognostic implications of periprocedural myocardial infarction (PMI) following percutaneous coronary interventions (PCI).
  • To discuss the varying definitions of PMI used in clinical trials and their association with patient outcomes.
  • To explore the prognostic value of cardiac biomarkers like creatine kinase-MB and troponin in the context of PMI.

Main Methods:

  • Review of existing clinical trial data and literature on periprocedural myocardial infarction (PMI) after percutaneous coronary intervention (PCI).
  • Analysis of diagnostic criteria for PMI, focusing on biomarker thresholds (creatine kinase-MB, troponin).
  • Evaluation of the prognostic significance of PMI and its relationship to underlying atherosclerotic burden.

Main Results:

  • A rise in creatine kinase-MB 3-8 times the upper limit of normal consistently predicts worse prognosis, indicating extensive and unstable atherosclerotic disease.
  • Conflicting data exists regarding the independent prognostic value of periprocedural troponin increases.
  • Some evidence suggests PMI may have a better prognosis than spontaneous myocardial infarction and its incidence may be reduced by aggressive antiplatelet and statin therapies.

Conclusions:

  • Periprocedural myocardial infarction (PMI) remains a significant complication of percutaneous coronary intervention (PCI) associated with reduced survival.
  • Biomarker elevation, particularly creatine kinase-MB, is crucial for assessing PMI severity and prognosis.
  • Further research is needed to clarify the role of troponin and optimize preventative strategies, including aggressive medical therapy, to reduce PMI incidence and improve outcomes.